Skip to content
ARWR·Nasdaq·US

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them, using RNA interference to knock down target genes. It has 18 discovered drug candidates in clinical trials, from Phase 1 to Phase 3, and its first commercial product, REDEMPLO (plozasiran), was FDA-approved in 2025 for adults with Familial Chylomicronemia Syndrome. It has also licensed programs to partners including Sarepta, Amgen, Takeda, GSK and Novartis.

Source: SEC 10-K Nov 25, 2025

Thematic Position

ARWR

Relationship Groups

Customers1
Partners5
Licensing7
Competitors6

Relationship details are part of the Pro plan.

Ended Relationships

12 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

armed conflict
Russia-Ukraine conflict shut down planned Arrowhead clinical trial sites in Russia, Ukraine and Belarus
SEC 10-KNov 25, 2025

The full regulatory passage is part of the Pro plan.